bioAffinity Technologies prices $4M private placement on Nasdaq

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, has entered into a securities purchase agreement with an institutional investor for a private placement offering expected to raise approximately $4.0 million in gross proceeds before fees and expenses.

The offering includes 8,462,027 shares of common stock, or pre-funded warrants in lieu thereof, along with two warrants to purchase up to an aggregate of 16,924,054 shares of common stock. The combined effective offering price per share of common stock and accompanying warrants is $0.4727. The combined effective offering price per pre-funded warrant and accompanying warrants is $0.4657.

The pre-funded warrants carry an exercise price of $0.007 per share, while the accompanying warrants have an exercise price of $0.4727 per share. The warrants will be exercisable following stockholder approval and will expire five years from the date of issuance.

The offering is priced at-the-market under Nasdaq rules and is structured as a private placement under Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D. The securities have not been registered under the Securities Act or applicable state securities laws.

The offering was expected to close on or about August 14, 2026, subject to customary closing conditions. WallachBeth Capital LLC served as the sole placement agent for the transaction. The company has agreed to provide customary registration rights for the shares underlying the warrants.

You May Also Be Interested In

• bioAffinity Technologies prices $4M private placement offering
• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• ZincFive and Spark I file draft S-4 for planned merger